Management of non-small cell lung cancer after 2 years of immunotherapy - 10/04/25
Experience of a French center
, Jacques Cadranel a, Constance Méteyé a, Samy Houari b, Lise Rosencher a, Christelle Epaud a, Jérémy Slomka a, Vincent Fallet a, Anthony Canellas aAbstract |
Background |
The optimal management strategy for metastatic or advanced-stage non-small-cell lung cancer (NSCLC) after 2 years of immune checkpoint inhibitor (ICI) remains unclear.
Methods |
We conducted a single-center retrospective observational study to characterize the management of patients who received at least 2 years of ICI in the first-line setting for a metastatic or advanced-stage NSCLC.
Results |
Among the 254 patients that received ICI in the first-line setting, 39 (15%) achieved 2 years of treatment (ICI in monotherapy, n = 14; ICI with chemotherapy, n = 25). ICI was discontinued after 2 years (<30 months) in 31 (79%) of the cases. During the first 2 years, 29 patients (74%) had no disease progression (2 complete radiological responses, 25 partial radiological responses, and 2 stable diseases) and 10 patients (26%) experienced at least one oligo-progression, which was treated with local ablative treatment (LAT), allowing continuation of ICI up to 2 years. A positron emission tomography (PET) scan was performed at 2 years for 37 patients (95%), revealing a complete metabolic response (CMR) in 16 individuals (43%). None of these patients progressed subsequently (median follow-up: 13 months). After 2 years of ICI, the 12-month progression-free survival was 100% in case of CMR versus 49% (95% CI, 29–91) in the absence of CMR (p = 0.00037).
Conclusions |
A CMR at 2 years of ICI is associated with a favorable prognosis. Further studies are needed to better establish the role of PET scan at 2 years, the relevance of LAT and the optimal duration of ICI.
Le texte complet de cet article est disponible en PDF.Keywords : Duration of therapy, Immune checkpoint inhibitors, Immunotherapy, Lung neoplasms, Non-small-cell lung carcinoma
Abbreviations : ALK, bMRI, CI, CMR, CR, CT, ECOG PS, EGFR, HR, ICI, LAT, L1, L+, NR, NSCLC, OR, ORR, OS, PFS, PET
Plan
Vol 87
Article 101169- mai 2025 Retour au numéro
Article précédent
- Phenotypes and prognosis of systemic sclerosis: A cluster analysis
- Stefan Nowak, Dany Jaffuel, Jacques Morel, Engi Ahmed, Anne Sophie Gamez, Clément Boissin, Jérémy Charriot, Nicolas Molinari, Arnaud Bourdin
- Progressive course of anti-nuclear matrix protein-2 (NXP-2) positive-interstitial lung disease
- Bess M. Flashner, Ryosuke Imai, Andrew J. Synn, Julia K. Munchel, Lida P. Hariri, Fiona K. Gibbons, Sydney B. Montesi, Barry S. Shea, Mary B. Rice, Rene S. Bermea, Robert W. Hallowell
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?